Drugs / SSGJ-613
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05966701 | Aug 2023 → Mar 2024 | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05027373 | Aug 2021 → Apr 2022 | periodic fever syndrome, systemic-onset juvenile idiopathic arthritis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05588908 | Jun 2022 → Sep 2023 | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07708181 | Aug 2026 → Aug 2027 expected | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06270225 | Mar → Oct 2024 | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06169891 | Dec 2023 → Dec 2024 | gout | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-613 | “Dose Arm 1 (phase Ib): SSGJ-613 100 mg subcutaneous (s.c) once.” NCT05588908 ↗5“Subjects will receive one s.c. injection of SSGJ-613 on Day 1.” NCT06270225 ↗ “SSGJ-613 200 mg subcutaneous (s.c) once.” NCT06169891 ↗ |
| Action | Inhibit | “anti-IL-1β” NCT05027373 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-IL-1β Humanized Monoclonal Antibody” NCT05027373 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT05027373 ↗ |